Literature DB >> 20570920

Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

Donal P McLornan1, Helen L Barrett, Robert Cummins, Ultan McDermott, Cliona McDowell, Susie J Conlon, Victoria M Coyle, Sandra Van Schaeybroeck, Richard Wilson, Elaine W Kay, Daniel B Longley, Patrick G Johnston.   

Abstract

PURPOSE: We previously found that cellular FLICE-inhibitory protein (c-FLIP), caspase 8, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor 2 (DR5) are major regulators of cell viability and chemotherapy-induced apoptosis in colorectal cancer. In this study, we determined the prognostic significance of c-FLIP, caspase 8, TRAIL and DR5 expression in tissues from patients with stage II and III colorectal cancer. EXPERIMENTAL
DESIGN: Tissue microarrays were constructed from matched normal and tumor tissue derived from patients (n = 253) enrolled in a phase III trial of adjuvant 5-fluorouracil-based chemotherapy versus postoperative observation alone. TRAIL, DR5, caspase 8, and c-FLIP expression levels were determined by immunohistochemistry.
RESULTS: Colorectal tumors displayed significantly higher expression levels of c-FLIP (P < 0.001), caspase 8 (P = 0.01), and DR5 (P < 0.001), but lower levels of TRAIL (P < 0.001) compared with matched normal tissue. In univariate analysis, higher TRAIL expression in the tumor was associated with worse overall survival (P = 0.026), with a trend to decreased relapse-free survival (RFS; P = 0.06), and higher tumor c-FLIP expression was associated with a significantly decreased RFS (P = 0.015). Using multivariate predictive modeling for RFS in all patients and including all biomarkers, age, treatment, and stage, we found that the model was significant when the mean tumor c-FLIP expression score and disease stage were included (P < 0.001). As regards overall survival, the overall model was predictive when both TRAIL expression and disease stage were included (P < 0.001).
CONCLUSIONS: High c-FLIP and TRAIL expression may be independent adverse prognostic markers in stage II and III colorectal cancer and might identify patients most at risk of relapse.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20570920      PMCID: PMC2896551          DOI: 10.1158/1078-0432.CCR-10-0052

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  42 in total

Review 1.  FLICE-inhibitory proteins: regulators of death receptor-mediated apoptosis.

Authors:  A Krueger; S Baumann; P H Krammer; S Kirchhoff
Journal:  Mol Cell Biol       Date:  2001-12       Impact factor: 4.272

Review 2.  Targeting death and decoy receptors of the tumour-necrosis factor superfamily.

Authors:  Avi Ashkenazi
Journal:  Nat Rev Cancer       Date:  2002-06       Impact factor: 60.716

3.  Increased expression of cFLIP(L) in colonic adenocarcinoma.

Authors:  B K Ryu; M G Lee; S G Chi; Y W Kim; J H Park
Journal:  J Pathol       Date:  2001-05       Impact factor: 7.996

4.  Expression of TRAIL and TRAIL receptors in colon carcinoma: TRAIL-R1 is an independent prognostic parameter.

Authors:  Jörn Sträter; Ulf Hinz; Henning Walczak; Gunhild Mechtersheimer; Karin Koretz; Christian Herfarth; Peter Möller; Thomas Lehnert
Journal:  Clin Cancer Res       Date:  2002-12       Impact factor: 12.531

5.  Silencing of death receptor and caspase-8 expression in small cell lung carcinoma cell lines and tumors by DNA methylation.

Authors:  S Hopkins-Donaldson; A Ziegler; S Kurtz; C Bigosch; D Kandioler; C Ludwig; U Zangemeister-Wittke; R Stahel
Journal:  Cell Death Differ       Date:  2003-03       Impact factor: 15.828

6.  Activation of NF-kappaB by FADD, Casper, and caspase-8.

Authors:  W H Hu; H Johnson; H B Shu
Journal:  J Biol Chem       Date:  2000-04-14       Impact factor: 5.157

7.  Expression of TRAIL (TNF-related apoptosis-inducing ligand) and its receptors in normal colonic mucosa, adenomas, and carcinomas.

Authors:  Jan J Koornstra; Jan H Kleibeuker; Caroline M M van Geelen; Fleur E M Rijcken; Harry Hollema; Elisabeth G E de Vries; Steven de Jong
Journal:  J Pathol       Date:  2003-07       Impact factor: 7.996

Review 8.  Immune escape of tumors: apoptosis resistance and tumor counterattack.

Authors:  Frederik H Igney; Peter H Krammer
Journal:  J Leukoc Biol       Date:  2002-06       Impact factor: 4.962

9.  TRAIL induced survival and proliferation in cancer cells resistant towards TRAIL-induced apoptosis mediated by NF-kappaB.

Authors:  Harald Ehrhardt; Simone Fulda; Irene Schmid; John Hiscott; Klaus-Michael Debatin; Irmela Jeremias
Journal:  Oncogene       Date:  2003-06-19       Impact factor: 9.867

10.  Targeting TNF-alpha for cancer therapy.

Authors:  Elizabeth R Burton; Steven K Libutti
Journal:  J Biol       Date:  2009-10-23
View more
  37 in total

1.  A quantitative systems approach to identify paracrine mechanisms that locally suppress immune response to Interleukin-12 in the B16 melanoma model.

Authors:  Yogesh M Kulkarni; Emily Chambers; A J Robert McGray; Jason S Ware; Jonathan L Bramson; David J Klinke
Journal:  Integr Biol (Camb)       Date:  2012-07-09       Impact factor: 2.192

2.  Prognostic significance of miR-215 in colon cancer.

Authors:  Mihriban Karaayvaz; Timothy Pal; Bo Song; Cecilia Zhang; Penelope Georgakopoulos; Saira Mehmood; Stephanie Burke; Kenneth Shroyer; Jingfang Ju
Journal:  Clin Colorectal Cancer       Date:  2011-07-12       Impact factor: 4.481

3.  HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL.

Authors:  Robbie Carson; Basak Celtikci; Patrick G Johnston; Sandra Van Schaeybroeck; Cathy Fenning; Arman Javadi; Nyree Crawford; Lucia Perez Carbonell; Mark Lawler; Daniel B Longley
Journal:  Clin Cancer Res       Date:  2015-03-26       Impact factor: 12.531

Review 4.  Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era.

Authors:  Patrick G Johnston
Journal:  Oncologist       Date:  2014-04-09

5.  STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers.

Authors:  Teppei Morikawa; Yoshifumi Baba; Mai Yamauchi; Aya Kuchiba; Katsuhiko Nosho; Kaori Shima; Noriko Tanaka; Curtis Huttenhower; David A Frank; Charles S Fuchs; Shuji Ogino
Journal:  Clin Cancer Res       Date:  2011-02-10       Impact factor: 12.531

6.  Identification of an acetylation-dependant Ku70/FLIP complex that regulates FLIP expression and HDAC inhibitor-induced apoptosis.

Authors:  E Kerr; C Holohan; K M McLaughlin; J Majkut; S Dolan; K Redmond; J Riley; K McLaughlin; I Stasik; M Crudden; S Van Schaeybroeck; C Fenning; R O'Connor; P Kiely; M Sgobba; D Haigh; P G Johnston; D B Longley
Journal:  Cell Death Differ       Date:  2012-02-10       Impact factor: 15.828

Review 7.  c-FLIP, a master anti-apoptotic regulator.

Authors:  A R Safa
Journal:  Exp Oncol       Date:  2012-10

8.  Effect of siRNA-mediated knockdown of eIF3c gene on survival of colon cancer cells.

Authors:  Ning Song; Yan Wang; Xiao-dong Gu; Zong-you Chen; Liu-bin Shi
Journal:  J Zhejiang Univ Sci B       Date:  2013-06       Impact factor: 3.066

9.  Identification of galanin and its receptor GalR1 as novel determinants of resistance to chemotherapy and potential biomarkers in colorectal cancer.

Authors:  Leanne Stevenson; Wendy L Allen; Richard Turkington; Puthen V Jithesh; Irina Proutski; Gail Stewart; Heinz-Josef Lenz; Sandra Van Schaeybroeck; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2012-08-02       Impact factor: 12.531

10.  Efficient drug delivery and induction of apoptosis in colorectal tumors using a death receptor 5-targeted nanomedicine.

Authors:  Daniela Schmid; Francois Fay; Donna M Small; Jakub Jaworski; Joel S Riley; Diana Tegazzini; Cathy Fenning; David S Jones; Patrick G Johnston; Daniel B Longley; Christopher J Scott
Journal:  Mol Ther       Date:  2014-07-23       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.